Literature DB >> 2529007

Interleukin-1 and hematopoiesis.

G C Bagby1.   

Abstract

Interleukin-1 alpha and interleukin-1 beta are 17.5 kDa peptides which exert a wide variety of biological activities. Both forms of interleukin bind to a common 60-70 kDa receptor expressed by most somatic cells. One major effect of interleukin-1 is to induce the expression of other genes, including genes for other interleukins (IL-6), colony stimulating factors (GM-CSF and G-CSF) and growth factors (PDGFA) and adhesion proteins (ELAM-1, ICAM-1). In vitro, cells of the hematopoietic stroma including thymic epithelium, endothelial cells, fibroblasts, T-lymphocytes, and macrophages, are all capable of responding to interleukin-1 by expressing most of these IL-1 inducible genes. Accordingly, because interleukin-1 has no direct effect on hematopoietic progenitor cells, its major effect on hematopoiesis is to regulate the expression of hematopoietic growth factor genes by other cells. The mechanism by which interleukin-1 induces gene expression is to first induce mRNA accumulation which accounts for an increase in translation of the mRNA. The accumulation of RNA, interestingly, does not result from increased transcription of these genes but by the stabilization of the mRNA. Ordinarily, the hematopoietic growth factor gene transcripts have a very short half-life but in an interleukin-1 induced cell, the half-life of these transcripts is markedly prolonged (greater than 24 h). This particular effect of IL-1 on transcript stability likely accounts for virtually all of the hematopoietic activities of interleukin-1 including: (1) induction of growth factors; (2) synergy with other factors; (3) priming; and (4) auto-induction. Three clinical models of hematopoiesis are presented which suggest that the interleukin-1 CSF network is operative in vivo. The ability of interleukin-1 to induce the expression of hematopoietic growth factor genes as well as genes whose products regulate cellular function and traffic suggest that interleukin-1 is an essential molecular master switch for a number of cellular responses occurring in organisms facing the vicissitudes of their environment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2529007     DOI: 10.1016/0268-960x(89)90012-x

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  11 in total

Review 1.  Moving from the laboratory bench to patients' bedside: considerations for effective therapy with stem cells.

Authors:  Lauren S Sherman; Jessian Munoz; Shyam A Patel; Meneka A Dave; Ilani Paige; Pranela Rameshwar
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

2.  Monocyte-derived CXCL7 peptides in the marrow microenvironment.

Authors:  Manoj M Pillai; Mineo Iwata; Norihiro Awaya; Lynn Graf; Beverly Torok-Storb
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

3.  IL-1 beta and IL-3-like activity in preterm infants.

Authors:  H Bessler; L Sirota; I Notti; F Dulitzky; M Djaldetti
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

4.  Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice.

Authors:  Y Niki; H Yamada; S Seki; T Kikuchi; H Takaishi; Y Toyama; K Fujikawa; N Tada
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

5.  Polymorphic variability in the interleukin (IL)-1beta promoter conditions susceptibility to severe malarial anemia and functional changes in IL-1beta production.

Authors:  Collins Ouma; Gregory C Davenport; Gordon A Awandare; Christopher C Keller; Tom Were; Michael F Otieno; John M Vulule; Jeremy Martinson; John M Ong'echa; Robert E Ferrell; Douglas J Perkins
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

6.  A morphological analysis of the short-term effects of benzene on the development of the hematological cells in the bone marrow of mice and the effects of interleukin-1 alpha on the process.

Authors:  R Niculescu; G F Kalf
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

7.  Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.

Authors:  M J Laughlin; G Kirkpatrick; N Sabiston; W Peters; J Kurtzberg
Journal:  Ann Hematol       Date:  1993-12       Impact factor: 3.673

8.  Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.

Authors:  Tony Navas; Li Zhou; Myka Estes; Edwin Haghnazari; Aaron N Nguyen; Yongkai Mo; Perry Pahanish; Mani Mohindru; Tim Cao; Linda S Higgins; Leonidas C Platanias; Alan List; Amit Verma; T Bhagat; S Gajavelli; S Kambhampati
Journal:  Leuk Lymphoma       Date:  2008-10

Review 9.  Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives.

Authors:  Ema Ozaki; Matthew Campbell; Sarah L Doyle
Journal:  J Inflamm Res       Date:  2015-01-16

Review 10.  The Role of IL-1 Family Members and Kupffer Cells in Liver Regeneration.

Authors:  Quanhui Tan; Jianjun Hu; Xiaolan Yu; Wen Guan; Huili Lu; Yan Yu; Yongsheng Yu; Guoqiang Zang; Zhenghao Tang
Journal:  Biomed Res Int       Date:  2016-03-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.